Literature DB >> 3456345

Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase.

K J Davies, J H Doroshow.   

Abstract

In the present study we have used beef heart submitochondrial preparations (BH-SMP) to demonstrate that a component of mitochondrial Complex I, probably the NADH dehydrogenase flavin, is the mitochondrial site of anthracycline reduction. During forward electron transport, the anthracyclines doxorubicin (Adriamycin) and daunorubicin acted as one-electron acceptors for BH-SMP (i.e. were reduced to semiquinone radical species) only when NADH was used as substrate; succinate and ascorbate were without effect. Inhibitor experiments (rotenone, amytal, piericidin A) indicated that the anthracycline reduction site lies on the substrate side of ubiquinone. Doxorubicin and daunorubicin semiquinone radicals were readily detected by ESR spectroscopy. Doxorubicin and daunorubicin semiquinone radicals (g congruent to 2.004, signal width congruent to 4.5 G) reacted avidly with molecular oxygen, presumably to produce O2-, to complete the redox cycle. The identification of Complex I as the site of anthracycline reduction was confirmed by studies of ATP-energized reverse electron transport using succinate or ascorbate as substrates, in the presence of antimycin A or KCN respiratory blocks. Doxorubicin and daunorubicin inhibited the reduction of NAD+ to NADH during reverse electron transport. Furthermore, during reverse electron transport in the absence of added NAD+, doxorubicin and daunorubicin addition caused oxygen consumption due to reduction of molecular oxygen (to O2-) by the anthracycline semiquinone radicals. With succinate as electron source both thenoyltrifluoroacetone (an inhibitor of Complex II) and rotenone blocked oxygen consumption, but with ascorbate as electron source only rotenone was an effective inhibitor. NADH oxidation by doxorubicin during BH-SMP forward electron transport had a KM of 99 microM and a Vmax of 30 nmol X min-1 X mg-1 (at pH 7.4 and 23 degrees C); values for daunorubicin were 71 microM and 37 nmol X min-1 X mg-1. Oxygen consumption at pH 7.2 and 37 degrees C exhibited KM values of 65 microM for doxorubicin and 47 microM for daunorubicin, and Vmax values of 116 nmol X min-1 X mg-1 for doxorubicin and 114 nmol X min-1 X mg-1 for daunorubicin. In marked contrast with these results, 5-iminodaunodrubicin (a new anthracycline with diminished cardiotoxic potential) exhibited little or no tendency to undergo reduction, or to redox cycle with BH-SMP. Redox cycling of anthracyclines by mitochondrial NADH dehydrogenase is shown, in the accompanying paper (Doroshow, J. H., and Davies, K. J. A. (1986) J. Biol. Chem. 261, 3068-3074), to generate O2-, H2O2, and OH which may underlie the cardiotoxicity of these antitumor agents.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3456345

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  136 in total

1.  Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury.

Authors:  Partha Mukhopadhyay; Bėla Horváth; Mohanraj Rajesh; Shingo Matsumoto; Keita Saito; Sándor Bátkai; Vivek Patel; Galin Tanchian; Rachel Y Gao; Benjamin F Cravatt; György Haskó; Pál Pacher
Journal:  Free Radic Biol Med       Date:  2010-11-09       Impact factor: 7.376

2.  Simple quantitative detection of mitochondrial superoxide production in live cells.

Authors:  Partha Mukhopadhyay; Mohanraj Rajesh; Kashiwaya Yoshihiro; György Haskó; Pál Pacher
Journal:  Biochem Biophys Res Commun       Date:  2007-04-25       Impact factor: 3.575

3.  The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle.

Authors:  Laura A A Gilliam; Kelsey H Fisher-Wellman; Chien-Te Lin; Jill M Maples; Brook L Cathey; P Darrell Neufer
Journal:  Free Radic Biol Med       Date:  2013-09-07       Impact factor: 7.376

4.  Is the combinational administration of doxorubicin and glutathione a reasonable proposal?

Authors:  Bo-Yu Shen; Chong Chen; Yang-Fan Xu; Jia-Jia Shen; Hui-Min Guo; Hao-Feng Li; Xi-Nuo Li; Dian Kang; Yu-Hao Shao; Zhang-Pei Zhu; Xiao-Xi Yin; Lin Xie; Guang-Ji Wang; Yan Liang
Journal:  Acta Pharmacol Sin       Date:  2018-09-14       Impact factor: 6.150

5.  Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin-induced cardiac and skeletal muscle myopathy.

Authors:  Kisuk Min; Oh-Sung Kwon; Ashley J Smuder; Michael P Wiggs; Kurt J Sollanek; Demetra D Christou; Jeung-Ki Yoo; Moon-Hyon Hwang; Hazel H Szeto; Andreas N Kavazis; Scott K Powers
Journal:  J Physiol       Date:  2015-02-23       Impact factor: 5.182

Review 6.  Drug-induced mitochondrial dysfunction and cardiotoxicity.

Authors:  Zoltán V Varga; Peter Ferdinandy; Lucas Liaudet; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-18       Impact factor: 4.733

Review 7.  Doxorubicin-induced apoptosis: implications in cardiotoxicity.

Authors:  B Kalyanaraman; Joy Joseph; Shashi Kalivendi; Suwei Wang; Eugene Konorev; Srigiridhar Kotamraju
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

Review 8.  Doxorubicin cardiomyopathy.

Authors:  Kanu Chatterjee; Jianqing Zhang; Norman Honbo; Joel S Karliner
Journal:  Cardiology       Date:  2009-12-11       Impact factor: 1.869

9.  Localization of the Enzyme System Involved in Anaerobic Reduction of Azo Dyes by Sphingomonas sp. Strain BN6 and Effect of Artificial Redox Mediators on the Rate of Azo Dye Reduction.

Authors:  M Kudlich; A Keck; J Klein; A Stolz
Journal:  Appl Environ Microbiol       Date:  1997-09       Impact factor: 4.792

10.  Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q.

Authors:  Karunakaran Chandran; Deepika Aggarwal; Raymond Q Migrino; Joy Joseph; Donna McAllister; Eugene A Konorev; William E Antholine; Jacek Zielonka; Satish Srinivasan; Narayan G Avadhani; B Kalyanaraman
Journal:  Biophys J       Date:  2009-02-18       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.